Roswell Park Comprehensive Cancer Center is recognized as one of the strongest cancer research programs in the country.
The Roswell Park Department of Medicine comprises over 40 full-time clinical and scientific faculty dedicated to direct patient care as well as cancer prevention, clinical, translational, and basic sciences research involving cancer patients and individuals at risk for cancer development. In addition, the Roswell Park research campus includes approximately 150 senior scientists within seven basic research and cancer prevention departments. From our founding in 1898, answering critical questions about the causes of cancer and its treatments has been a core element of our mission at Roswell Park Comprehensive Cancer Center. We are an international epicenter for major advances in cancer diagnosis and treatment.
With funding from the National Cancer Institute’s Cancer Center Support Grant (CCSG), Roswell Park makes new discoveries about cancer every day. Roswell Park has four CCSG Programs organized around common areas of scientific interest – Tumor immunology and Immunotherapy, Developmental Therapeutics, Cell Stress and Biophysical Therapies, and Population Science, equipped with state-of-the-art laboratories, shared resources, and a rich history of multidisciplinary collaboration. The CCSG programs at Rowell Park also work closely with our experts in community outreach, health disparities and cancer prevention to develop and offer integrated community-based services and educational programs tailored to meet the needs of vulnerable populations.
Fellows in Roswell Park’s Hematology and Medical Oncology program work closely with program members as well as trainees in Master’s and PhD programs, participating in all phases of basic and translational research. Faculty mentors available to train the next generation of clinical, translational, and basic researchers in hematology and oncology can be found in the Roswell Park Department of Medicine, any of Roswell Park’s basic research and cancer prevention scientific departments, and the University at Buffalo’s School of Medicine and Biomedical Sciences. See Roswell Park Department of Medicine links for Roswell Park faculty listing and research interests, and the UB Division of Hematology for information about affiliated UB faculty.
Read more about research projects our current fellows have participated in, notable awards they have received, and presentations at major international conferences.
- Comorbidity burden of cancer survivors in the United States.
- Transportation barriers and mortality in patients with history of cancer in the US.
- Association between Medicaid Expansion and Timely Neoadjuvant therapy in Muscle invasive Bladder Cancer.
- Utilizing artificial intelligence to develop a non-invasive radiomics based biomarker to predict response to chemoimmunotherapy in extended stage small cell lung cancer.
- Survival benefits of chemotherapy in bladder cancer with variant and non-urothelial histologies.
- Single agent immunotherapy as frontline treatment for metastatic renal cell cancer.
- Survival Outcomes of Pulmonary Sarcomatoid Carcinoma Treated in the Era of Immune Checkpoint Inhibitors.
- Perioperative ctDNA analysis in Gastroesophageal Cancer.
- Enhancing anti-tumoral immune responses through beta adrenergic receptor blockade.
- Older patients with T cell lymphoma – a single center experience.
- Professional Development in Twitter Heme Onc fellows’ network.
- Early Complete Remission by Functional Imaging and Intensified Frontline Therapy are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience.
- Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT).
- Ultradeep sequencing to identify clonal mutations in non-small cell lung cancer.
- Hypomethylating Agents in Acute Myeloid Leukemia.
- Impact of higher environmental temperature on tumor microenvironment, chemotherapy responses, and clinical outcomes in breast cancer.
- Impact of race on long-term outcomes after neoadjuvant chemotherapy in breast cancer.
- Investigating ASXL1 mutation as a novel risk factor for bleeding in patients with philadelphia-negative myeloproliferative neoplasms (MPN).
- Studying the effect of Gemtuzumab Ozogamicin added to standard induction therapy in intermediate risk acute myeloid leukemia.
- Education Award of IASCL North America Conference on Lung Cancer 2022
- CAHON Young Investigator Award 2022
- ASCO Conquer Cancer Merit award 2022 GU symposium
- Charlie and Gloria Carbone Young Investigator in Training award 2022
- ASCO Conquer Cancer Merit award 2022 Annual Meeting
- AACR/ASCO Workshop on Methods in Clinical Cancer Research (VAIL workshop) 2022
- IASLC Targeted Therapies of Lung Cancer Meeting 2022
- Thomas F Frawley Research Fellowship Award 2022
- Charlie and Gloria Carbone Young Investigator in Training award 2021
- ASCO Conquer Cancer Merit award 2021 Quality symposium
- American Society of Clinical Oncology (ASCO) Annual and Disease Subgroup Meetings
- American Association for Cancer Research (AACR) Annual Meeting
- American Society of Hematology (ASH) Annual Meeting
- National Comprehensive Cancer Network (NCCN) Annual Conference
- European Society for Medical Oncology (ESMO) Annual Meeting
- San Antonio Breast Cancer Symposium
- Internal Association for the Study of Lung Cancer Annual Conferences
- Thrombosis and Hemostasis Society of North America Summit
- Society for Immunotherapy of Cancer Annual Meeting